nach oben

Current Diabetes Reports

Erschienen in:

01.08.2014 | Microvascular Complications—Nephropathy (B Roshan, Section Editor)

Novel Urinary Biomarkers in Early Diabetic Kidney Disease

verfasst von: Atsuko Kamijo-Ikemori, Takeshi Sugaya, Kenjiro Kimura

Erschienen in: Current Diabetes Reports | Ausgabe 8/2014

Einloggen, um Zugang zu erhalten

Abstract

In diabetic kidney disease, detection of urinary albumin is recommended to aid in diagnosis, evaluate disease severity, and determine effects of therapy. However, because typical histopathologic changes in diabetic kidney disease or early progressive renal decline may occur in patients with normoalbuminuria, urinary albumin may not be sufficient to identify patients with early-stage diabetic kidney disease or to predict its progression. Therefore, intensive efforts have been made to identify novel noninvasive urinary biomarkers to discriminate patients with a higher risk of end-stage renal failure. Because diabetic kidney disease progression is associated with the extent of histologic changes in the glomeruli and the degree of tubulointerstitial changes, urinary biomarkers that accurately reflect the degree of histopathologic damage may be excellent biomarkers. This review article summarizes the clinical significance of new urinary biomarkers in the early detection of diabetic kidney disease.

Parving H, Mauer M, Fioretto P, Rossing P, Ritz E. Diabetic nephropathy. The Kidney. Philadelphia: Elsevier Saunders; 2012. p. 1411–54.

Creager MA, Luscher TF, Cosentino F, Beckman JA. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part I. Circulation. 2003;108:1527–32.PubMedCrossRef

Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–8.PubMedCentralPubMedCrossRef

Luscher TF, Creager MA, Beckman JA, Cosentino F. Diabetes and vascular disease: pathophysiology, clinical consequences, and medical therapy: Part II. Circulation. 2003;108:1655–61.PubMedCrossRef

Woodward M, Zhang X, Barzi F, Pan W, Ueshima H, Rodgers A, et al. The effects of diabetes on the risks of major cardiovascular diseases and death in the Asia-Pacific region. Diabetes Care. 2003;26:360–6.PubMedCrossRef

Kimmelstiel P, Wilson C. Intercapillary lesions in the glomeruli of the kidney. Am J Pathol. 1936;12:83–98.PubMedCentralPubMed

Tervaert TW, Mooyaart AL, Amann K, Cohen AH, Cook HT, Drachenberg CB, et al. Pathologic classification of diabetic nephropathy. J Am Soc Nephrol. 2010;21:556–63.PubMedCrossRef

Caramori ML, Fioretto P, Mauer M. Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions. Diabetes. 2003;52:1036–40.PubMedCrossRef

9.•

Caramori ML, Parks A, Mauer M. Renal lesions predict progression of diabetic nephropathy in type 1 diabetes. J Am Soc Nephrol. 2013;24:1175–81. This article shows that GBM width in patients with long-standing type 1 diabetes is a strong independent predictor of progression of diabetic kidney disease in those with normoalbuminuria. PubMedCentralPubMedCrossRef

10.

Oh SW, Kim S, Na KY, Chae DW, Jin DC, Chin HJ. Clinical implications of pathologic diagnosis and classification for diabetic nephropathy. Diabetes Res Clin Pract. 2012;97:418–24.PubMedCrossRef

11.

Levey AS, de Jong PE, Coresh J, El Nahas M, Astor BC, Matsushita K, et al. The definition, classification, and prognosis of chronic kidney disease: a KDIGO Controversies Conference report. Kidney Int. 2011;80:17–28.PubMedCrossRef

12.

Wada T, Haneda M, Furuichi K, Babazono T, Yokoyama H, Iseki K, et al. The Research Group of Diabetic Nephropathy MoH, Labour, and Welfare of Japan. Clinical impact of albuminuria and glomerular filtration rate on renal and cardiovascular events, and all-cause mortality in Japanese patients with type 2 diabetes. Clin Exp Nephrol. 2014; [In press].

13.

Haller H, Ito S, Izzo Jr JL, Januszewicz A, Katayama S, Menne J, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med. 2011;364:907–17.PubMedCrossRef

14.

Berhane AM, Weil EJ, Knowler WC, Nelson RG, Hanson RL. Albuminuria and estimated glomerular filtration rate as predictors of diabetic end-stage renal disease and death. Clin J Am Soc Nephrol. 2011;6:2444–51.PubMedCentralPubMedCrossRef

15.

Drury PL, Ting R, Zannino D, Ehnholm C, Flack J, Whiting M, et al. Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetologia. 2011;54:32–43.PubMedCrossRef

16.

Molitch ME, Steffes M, Sun W, Rutledge B, Cleary P, de Boer IH, et al. Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study. Diabetes Care. 2010;33:1536–43.PubMedCentralPubMedCrossRef

17.

Ninomiya T, Perkovic V, de Galan BE, Zoungas S, Pillai A, Jardine M, et al. Albuminuria and kidney function independently predict cardiovascular and renal outcomes in diabetes. J Am Soc Nephrol. 2009;20:1813–21.PubMedCentralPubMedCrossRef

18.

Toyama T, Furuichi K, Ninomiya T, Shimizu M, Hara A, Iwata Y, et al. The impacts of albuminuria and low eGFR on the risk of cardiovascular death, all-cause mortality, and renal events in diabetic patients: meta-analysis. PLoS One. 2013;8:e71810.PubMedCentralPubMedCrossRef

19.

Yokoyama H, Sone H, Oishi M, Kawai K, Fukumoto Y, Kobayashi M. Prevalence of albuminuria and renal insufficiency and associated clinical factors in type 2 diabetes: the Japan Diabetes Clinical Data Management study (JDDM15). Nephrol Dial Transplant. 2009;24:1212–9.PubMedCrossRef

20.•

Krolewski AS, Niewczas MA, Skupien J, Gohda T, Smiles A, Eckfeldt JH, et al. Early progressive renal decline precedes the onset of microalbuminuria and its progression to macroalbuminuria. Diabetes Care. 2014;37:226–34. This article shows that progressive renal decline, not abnormalities in urinary albumin excretion, occur as the major feature of disease processes leading to ESRD in type 1 diabetes. PubMedCrossRef

21.

Retnakaran R, Cull CA, Thorne KI, Adler AI, Holman RR. Risk factors for renal dysfunction in type 2 diabetes: U.K. Prospective Diabetes Study 74. Diabetes. 2006;55:1832–9.PubMedCrossRef

22.•

Shimizu M, Furuichi K, Toyama T, Kitajima S, Hara A, Kitagawa K, et al. Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy. Diabetes Care. 2013;36:3655–62. This article reveals a relationship between histopathologic changes and prognosis of diabetic kidney disease in type 2 diabetic patients. PubMedCrossRef

23.

de Boer IH, Rue TC, Hall YN, Heagerty PJ, Weiss NS, Himmelfarb J. Temporal trends in the prevalence of diabetic kidney disease in the United States. JAMA. 2011;305:2532–9.PubMedCentralPubMedCrossRef

24.

Gilbert RE, Cooper ME. The tubulointerstitium in progressive diabetic kidney disease: more than an aftermath of glomerular injury? Kidney Int. 1999;56:1627–37.PubMedCrossRef

25.

Magri CJ, Fava S. The role of tubular injury in diabetic nephropathy. Eur J Intern Med. 2009;20:551–5.PubMedCrossRef

26.

Ziyadeh FN. Significance of tubulointerstitial changes in diabetic renal disease. Kidney Int Suppl. 1996;54:S10–3.PubMed

27.

Okada T, Nagao T, Matsumoto H, Nagaoka Y, Wada T, Nakao T. Histological predictors for renal prognosis in diabetic nephropathy in diabetes mellitus type 2 patients with overt proteinuria. Nephrology (Carlton). 2012;17:68–75.CrossRef

28.

Nangaku M. Chronic hypoxia and tubulointerstitial injury: a final common pathway to end-stage renal failure. J Am Soc Nephrol. 2006;17:17–25.PubMedCrossRef

29.

Singh DK, Winocour P, Farrington K. Mechanisms of disease: the hypoxic tubular hypothesis of diabetic nephropathy. Nat Clin Pract Nephrol. 2008;4:216–26.PubMedCrossRef

30.

Palm F, Cederberg J, Hansell P, Liss P, Carlsson PO. Reactive oxygen species cause diabetes-induced decrease in renal oxygen tension. Diabetologia. 2003;46:1153–60.PubMedCrossRef

31.

Anderson S. Role of local and systemic angiotensin in diabetic renal disease. Kidney Int Suppl. 1997;63:S107–10.PubMed

32.

dos Santos EA, Li LP, Ji L, Prasad PV. Early changes with diabetes in renal medullary hemodynamics as evaluated by fiber optic probes and BOLD magnetic resonance imaging. Invest Radiol. 2007;42:157–62.PubMedCentralPubMedCrossRef

33.

Yin WJ, Liu F, Li XM, Yang L, Zhao S, Huang ZX, et al. Noninvasive evaluation of renal oxygenation in diabetic nephropathy by BOLD-MRI. Eur J Radiol. 2012;81:1426–31.PubMedCrossRef

34.•

Moresco RN, Sangoi MB, De Carvalho JA, Tatsch E, Bochi GV. Diabetic nephropathy: traditional to proteomic markers. Clin Chim Acta. 2013;421:17–30. This review summarizes the clinical significance of markers reported in diabetic kidney disease, including the preliminary markers. PubMedCrossRef

35.

Boussageon R, Bejan-Angoulvant T, Saadatian-Elahi M, Lafont S, Bergeonneau C, Kassai B, et al. Effect of intensive glucose lowering treatment on all-cause mortality, cardiovascular death, and microvascular events in type 2 diabetes: meta-analysis of randomized controlled trials. BMJ. 2011;343:d4169.PubMedCentralPubMedCrossRef

36.

de Galan BE, Perkovic V, Ninomiya T, Pillai A, Patel A, Cass A, et al. Lowering blood pressure reduces renal events in type 2 diabetes. J Am Soc Nephrol. 2009;20:883–92.PubMedCentralPubMedCrossRef

37.

Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360:129–39.PubMedCrossRef

38.

Ismail-Beigi F, Craven T, Banerji MA, Basile J, Calles J, Cohen RM, et al. Effect of intensive treatment of hyperglycaemia on microvascular outcomes in type 2 diabetes: an analysis of the ACCORD randomized trial. Lancet. 2010;376:419–30.PubMedCrossRef

39.

Inker LA, Schmid CH, Tighiouart H, Eckfeldt JH, Feldman HI, Greene T, et al. Estimating glomerular filtration rate from serum creatinine and cystatin C. N Engl J Med. 2012;367:20–9.PubMedCrossRef

40.

Perkins BA, Ficociello LH, Ostrander BE, Silva KH, Weinberg J, Warram JH, et al. Microalbuminuria and the risk for early progressive renal function decline in type 1 diabetes. J Am Soc Nephrol. 2007;18:1353–61.PubMedCrossRef

41.

Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRef

42.

Chavers BM, Mauer SM, Ramsay RC, Steffes MW. Relationship between retinal and glomerular lesions in IDDM patients. Diabetes. 1994;43:441–6.PubMedCrossRef

43.

Hansen KW, Mau Pedersen M, Christensen CK, Schmitz A, Christiansen JS, Mogensen CE. Normoalbuminuria ensures no reduction of renal function in type 1 (insulin-dependent) diabetic patients. J Intern Med. 1992;232:161–7.PubMedCrossRef

44.

Silveiro SP, Friedman R, de Azevedo MJ, Canani LH, Gross JL. Five-year prospective study of glomerular filtration rate and albumin excretion rate in normofiltering and hyperfiltering normoalbuminuric NIDDM patients. Diabetes Care. 1996;19:171–4.PubMedCrossRef

45.

Ruggenenti P, Porrini E, Motterlini N, Perna A, Ilieva AP, Iliev IP, et al. Measurable urinary albumin predicts cardiovascular risk among normoalbuminuric patients with type 2 diabetes. J Am Soc Nephrol. 2012;23:1717–24.PubMedCentralPubMedCrossRef

46.

Shankland SJ. The podocyte's response to injury: role in proteinuria and glomerulosclerosis. Kidney Int. 2006;69:2131–47.PubMedCrossRef

47.

Dalla Vestra M, Masiero A, Roiter AM, Saller A, Crepaldi G, Fioretto P. Is podocyte injury relevant in diabetic nephropathy? Studies in patients with type 2 diabetes. Diabetes. 2003;52:1031–5.PubMedCrossRef

48.

Weil EJ, Lemley KV, Mason CC, Yee B, Jones LI, Blouch K, et al. Podocyte detachment and reduced glomerular capillary endothelial fenestration promote kidney disease in type 2 diabetic nephropathy. Kidney Int. 2012;82:1010–7.PubMedCentralPubMedCrossRef

49.

Nielsen JS, McNagny KM. The role of podocalyxin in health and disease. J Am Soc Nephrol. 2009;20:1669–76.PubMedCrossRef

50.

Hara M, Yanagihara T, Kihara I, Higashi K, Fujimoto K, Kajita T. Apical cell membranes are shed into urine from injured podocytes: a novel phenomenon of podocyte injury. J Am Soc Nephrol. 2005;16:408–16.PubMedCrossRef

51.•

Hara M, Yamagata K, Tomino Y, Saito A, Hirayama Y, Ogasawara S, et al. Urinary podocalyxin is an early marker for podocyte injury in patients with diabetes: establishment of a highly sensitive ELISA to detect urinary podocalyxin. Diabetologia. 2012;55:2913–9. This article discusses the establishment of a sensitive ELISA for detecting urinary podocalyxin and the clinical significance of urinary podocalyxin in type 2 diabetes. PubMedCentralPubMedCrossRef

52.

Ye H, Bai X, Gao H, Li L, Wu C, Sun X, et al. Urinary podocalyxin positive-element occurs in the early stage of diabetic nephropathy and is correlated with a clinical diagnosis of diabetic nephropathy. J Diabetes Complicat. 2014;28:96–100.PubMedCrossRef

53.

Nakamura T, Ushiyama C, Suzuki S, Hara M, Shimada N, Ebihara I, et al. Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant. 2000;15:1379–83.PubMedCrossRef

54.

Su AI, Wiltshire T, Batalov S, Lapp H, Ching KA, Block D, et al. A gene atlas of the mouse and human protein-encoding transcriptomes. Proc Natl Acad Sci U S A. 2004;101:6062–7.PubMedCentralPubMedCrossRef

55.

Kamijo-Ikemori A, Sugaya T, Matsui K, Yokoyama T, Kimura K. Roles of human liver type fatty acid binding protein in kidney disease clarified using hL-FABP chromosomal transgenic mice. Nephrology (Carlton). 2011;16:539–44.CrossRef

56.

Kamijo A, Sugaya T, Hikawa A, Okada M, Okumura F, Yamanouchi M, et al. Urinary excretion of fatty acid-binding protein reflects stress overload on the proximal tubules. Am J Pathol. 2004;165:1243–55.PubMedCentralPubMedCrossRef

57.

Kamijo-Ikemori A, Sugaya T, Sekizuka A, Hirata K, Kimura K. Amelioration of diabetic tubulointerstitial damage in liver-type fatty acid-binding protein transgenic mice. Nephrol Dial Transplant. 2009;24:788–800.PubMedCrossRef

58.•

Kamijo-Ikemori A, Sugaya T, Ichikawa D, Hoshino S, Matsui K, Yokoyama T, et al. Urinary liver type fatty acid binding protein in diabetic nephropathy. Clin Chim Acta. 2013;23:104–8. We summarize the clinical usefulness of urinary L-FABP in diabetic kidney disease. CrossRef

59.•

Kamijo-Ikemori A, Sugaya T, Yasuda T, Kawata T, Ota A, Tatsunami S, et al. Clinical significance of urinary liver-type fatty acid-binding protein in diabetic nephropathy of type 2 diabetic subjects. Diabetes Care. 2011;34:691–6. This article reports the clinical significance of urinary L-FABP in type 2 diabetes and the upper limit value of urinary L-FABP in healthy control patients. PubMedCentralPubMedCrossRef

60.•

Nielsen SE, Sugaya T, Tarnow L, Lajer M, Schjoedt KJ, Astrup AS, et al. Tubular and glomerular injury in diabetes and the impact of ACE inhibition. Diabetes Care. 2009;32:1684–8. This article shows a relationship between urinary L-FABP level and the severity of diabetic kidney disease. PubMedCentralPubMedCrossRef

61.••

Panduru N, Forsblom C, Saraheimo M, Thorn L, Humpert P, Groop P. Urinary liver-type fatty acid-binding protein and progression of diabetic nephropathy in type 1 diabetes. Diabetes Care. 2013;36:2077–83. This large-scale clinical trial of type 1 diabetes shows great potential for urinary L-FABP as a predictor of progression across all stages of diabetic kidney disease. PubMedCentralPubMedCrossRef

62.

Yamamoto T, Noiri E, Ono Y, Doi K, Negishi K, Kamijo A, et al. Renal L-type fatty acid–binding protein in acute ischemic injury. J Am Soc Nephrol. 2007;18:2894–902.PubMedCrossRef

63.

von Eynatten M, Baumann M, Heemann U, Zdunek D, Hess G, Nawroth PP, et al. Urinary L-FABP and anaemia: distinct roles of urinary markers in type 2 diabetes. Eur J Clin Invest. 2010;40:95–102.CrossRef

64.•

Nielsen SE, Sugaya T, Hovind P, Baba T, Parving HH, Rossing P. Urinary liver-type fatty acid-binding protein (u-LFABP) predicts progression to nephropathy in type 1 diabetic patients. Diabetes Care. 2010;33:1320–4. This article emphasizes that an increase in urinary L-FABP level is significantly associated with progression of diabetic kidney disease in type 1 diabetes with normoalbuminuria. PubMedCentralPubMedCrossRef

65.

Chou KM, Lee CC, Chen CH, Sun CY. Clinical value of NGAL, L-FABP and albuminuria in predicting GFR Decline in type 2 diabetes mellitus patients. PLoS One. 2013;8:e54863.PubMedCentralPubMedCrossRef

66.••

Araki S, Haneda M, Koya D, Sugaya T, Icchiki K, Kume S, et al. Predictive effects of urinary liver-type fatty acid-binding protein for deteriorating renal function and incidence of cardiovascular disease in type 2 diabetic patients without advanced nephropathy. Diabetes Care. 2013;36:1248–53. This large-scale clinical trial of type 2 diabetes shows great potential for urinary L-FABP as a predictor of diabetic kidney disease progression and cardiovascular events. PubMedCentralPubMedCrossRef

67.

Maeda Y, Suzuki A, Ishii J, Sekiguchi-Ueda S, Shibata M, Yoshino Y, et al. Level of urinary liver-type fatty acid-binding protein is associated with cardiac markers and electrocardiographic abnormalities in type-2 diabetes with chronic kidney disease stage G1 and G2. Heart Vessels. 2014; [In press].

68.

Okada H, Kikuta T, Kobayashi T, Inoue T, Kanno Y, Takigawa M, et al. Connective tissue growth factor expressed in tubular epithelium plays a pivotal role in renal fibrogenesis. J Am Soc Nephrol. 2005;16:133–43.PubMedCrossRef

69.

Roestenberg P, van Nieuwenhoven FA, Joles JA, Trischberger C, Martens PP, Oliver N, et al. Temporal expression profile and distribution pattern indicate a role of connective tissue growth factor (CTGF/CCN-2) in diabetic nephropathy in mice. Am J Physiol Ren Physiol. 2006;290:F1344–54.CrossRef

70.

Kobayashi T, Okada H, Inoue T, Kanno Y, Suzuki H. Tubular expression of connective tissue growth factor correlates with interstitial fibrosis in type 2 diabetic nephropathy. Nephrol Dial Transplant. 2006;21:548–9.PubMedCrossRef

71.

Nguyen TQ, Tarnow L, Andersen S, Hovind P, Parving HH, Goldschmeding R, et al. Urinary connective tissue growth factor excretion correlates with clinical markers of renal disease in a large population of type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2006;29:83–8.PubMedCrossRef

72.

Tam FW, Riser BL, Meeran K, Rambow J, Pusey CD, Frankel AH. Urinary monocyte chemoattractant protein-1 (MCP-1) and connective tissue growth factor (CCN2) as prognostic markers for progression of diabetic nephropathy. Cytokine. 2009;47:37–42.PubMedCrossRef

73.

Andersen S, van Nieuwenhoven FA, Tarnow L, Rossing P, Rossing K, Wieten L, et al. Reduction of urinary connective tissue growth factor by Losartan in type 1 patients with diabetic nephropathy. Kidney Int. 2005;67:2325–9.PubMedCrossRef

74.

Gilbert RE, Akdeniz A, Weitz S, Usinger WR, Molineaux C, Jones SE, et al. Urinary connective tissue growth factor excretion in patients with type 1 diabetes and nephropathy. Diabetes Care. 2003;26:2632–6.PubMedCrossRef

75.•

O'Seaghdha CM, Hwang SJ, Bhavsar NA, Kottgen A, Coresh J, Astor BC, et al. Lower urinary connective tissue growth factor levels and incident CKD stage 3 in the general population. Am J Kidney Dis. 2011;57:841–9. This study indicated the results, which contradicted the prevailing recognition of urinary CTGF in diabetic kidney disease. PubMedCrossRef

Titel: Novel Urinary Biomarkers in Early Diabetic Kidney Disease
verfasst von: Atsuko Kamijo-Ikemori
Takeshi Sugaya
Kenjiro Kimura
Publikationsdatum: 01.08.2014
Verlag: Springer US
Erschienen in: Current Diabetes Reports / Ausgabe 8/2014
Print ISSN: 1534-4827
Elektronische ISSN: 1539-0829
DOI: https://doi.org/10.1007/s11892-014-0513-1

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

25.04.2024 Allergien und Intoleranzreaktionen Nachrichten

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Springer Medizin

Abstract

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 8/2014

Anti-VEGF Therapy for Diabetic Macular Edema

Cystic Fibrosis Related Diabetes

Obesity and Type 2 Diabetes in Children: Epidemiology and Treatment

Goal Setting: An Integral Component of Effective Diabetes Care

Genetics of Diabetic Retinopathy